+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Oncology Clinical Trial Market 2021-2025

  • PDF Icon

    Report

  • 120 Pages
  • November 2021
  • Region: Global
  • TechNavio
  • ID: 5514870
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the oncology clinical trial market and it is poised to grow by $4.22 bn during 2021-2025, progressing at a CAGR of 6.70% during the forecast period. The report on the oncology clinical trial market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing number of cancer cases across the globe and the growing need for personalized medicines.

The oncology clinical trial market analysis includes the design segment and geographic landscape.

The oncology clinical trial market is segmented as below:


By Design

  • Interventional
  • Observational
  • Expanded access

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the rise in the research and development activities for oncology as one of the prime reasons driving the oncology clinical trial market growth during the next few years.

The report on oncology clinical trial market covers the following areas:

  • Oncology clinical trial market sizing
  • Oncology clinical trial market forecast
  • Oncology clinical trial market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading oncology clinical trial market vendors that include F. Hoffmann-La Roche Ltd., Icon Plc, IQVIA Holdings Inc., Medpace Holdings Inc., Merck and Co. Inc., Novartis AG, Novotech (Australia) Pty Ltd., Parexel International Corp., Pivotal S.L.U, and Syneos Health Inc. Also, the oncology clinical trial market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

Executive Summary
  • Market Overview

Market Landscape
  • Market ecosystem
  • Value chain analysis

Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Design
  • Market segments
  • Comparison by Design
  • Interventional - Market size and forecast 2020-2025
  • Observational - Market size and forecast 2020-2025
  • Expanded Access - Market size and forecast 2020-2025
  • Market opportunity by Design

Customer landscape

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity By Geographical Landscape
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape
  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • F. Hoffmann-La Roche Ltd.
  • Icon Plc
  • IQVIA Holdings Inc.
  • Medpace Holdings Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Novotech (Australia) Pty Ltd.
  • Parexel International Corp.
  • Pivotal S.L.U
  • Syneos Health Inc.

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Design - Market share 2020-2025 (%)
  • Comparison by Design
  • Interventional - Market size and forecast 2020-2025 ($ million)
  • Interventional - Year-over-year growth 2020-2025 (%)
  • Observational - Market size and forecast 2020-2025 ($ million)
  • Observational - Year-over-year growth 2020-2025 (%)
  • Expanded Access - Market size and forecast 2020-2025 ($ million)
  • Expanded Access - Year-over-year growth 2020-2025 (%)
  • Market opportunity by Design
  • Customer landscape
  • Market share By Geographical Landscape 2020-2025 (%)
  • Geographic comparison
  • North America - Market size and forecast 2020-2025 ($ million)
  • North America - Year-over-year growth 2020-2025 (%)
  • Europe - Market size and forecast 2020-2025 ($ million)
  • Europe - Year-over-year growth 2020-2025 (%)
  • Asia - Market size and forecast 2020-2025 ($ million)
  • Asia - Year-over-year growth 2020-2025 (%)
  • ROW - Market size and forecast 2020-2025 ($ million)
  • ROW - Year-over-year growth 2020-2025 (%)
  • Key leading countries
  • Market opportunity By Geographical Landscape ($ million)
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • F. Hoffmann-La Roche Ltd. - Overview
  • F. Hoffmann-La Roche Ltd. - Business segments
  • F. Hoffmann-La Roche Ltd. - Key offerings
  • F. Hoffmann-La Roche Ltd. - Key customers
  • F. Hoffmann-La Roche Ltd. - Segment focus
  • Icon Plc - Overview
  • Icon Plc - Product and service
  • Icon Plc - Key offerings
  • Icon Plc - Key customers
  • Icon Plc - Segment focus
  • IQVIA Holdings Inc. - Overview
  • IQVIA Holdings Inc. - Business segments
  • IQVIA Holdings Inc. - Key offerings
  • IQVIA Holdings Inc. - Key customers
  • IQVIA Holdings Inc. - Segment focus
  • Medpace Holdings Inc. - Overview
  • Medpace Holdings Inc. - Business segments
  • Medpace Holdings Inc. - Key offerings
  • Medpace Holdings Inc. - Key customers
  • Medpace Holdings Inc. - Segment focus
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Key customers
  • Merck and Co. Inc. - Segment focus
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key offerings
  • Novartis AG - Key customers
  • Novartis AG - Segment focus
  • Novotech (Australia) Pty Ltd. - Overview
  • Novotech (Australia) Pty Ltd. - Product and service
  • Novotech (Australia) Pty Ltd. - Key offerings
  • Novotech (Australia) Pty Ltd. - Key customers
  • Novotech (Australia) Pty Ltd. - Segment focus
  • Parexel International Corp. - Overview
  • Parexel International Corp. - Product and service
  • Parexel International Corp. - Key offerings
  • Parexel International Corp. - Key customers
  • Parexel International Corp. - Segment focus
  • Pivotal S.L.U - Overview
  • Pivotal S.L.U - Product and service
  • Pivotal S.L.U - Key offerings
  • Pivotal S.L.U - Key customers
  • Pivotal S.L.U - Segment focus
  • Syneos Health Inc. - Overview
  • Syneos Health Inc. - Business segments
  • Syneos Health Inc. - Key offerings
  • Syneos Health Inc. - Key customers
  • Syneos Health Inc. - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global oncology clinical trial market: F. Hoffmann-La Roche Ltd., Icon Plc, IQVIA Holdings Inc., Medpace Holdings Inc., Merck and Co. Inc., Novartis AG, Novotech (Australia) Pty Ltd., Parexel International Corp., Pivotal S.L.U, and Syneos Health Inc.

Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is rise in the research and development activities for oncology.`

According to the report, one of the major drivers for this market is the increasing number of cancer cases across globe.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • F. Hoffmann-La Roche Ltd.
  • Icon Plc
  • IQVIA Holdings Inc.
  • Medpace Holdings Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Novotech (Australia) Pty Ltd.
  • Parexel International Corp.
  • Pivotal S.L.U
  • Syneos Health Inc.